ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for Access

September 14, 2021

On September 9, the U.S. Department of Health Human Services (HHS) released a report titled, Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy. The report comes following president Biden’s July 2021 Executive Order 14036, “Promoting Competition in the American Economy” (the Competition Executive Order), which directed HHS to publish a report presenting principles of prescription drug pricing reform.

September 2, 2021

The American Society of Clinical Oncology (ASCO) has a list of resources and information to support cancer care providers and patients affected by natural disasters such as Hurricane Ida.

August 20, 2021

On August 19, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.

August 19, 2021

On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 

August 13, 2021

The White House is hosting a virtual conversation for health care providers on the COVID-19 vaccination effort. All ASCO members are encouraged to attend.

August 6, 2021

The Association for Clinical Oncology (ASCO) commends the Biden Administration for proposing to rescind the Most Favored Nation (MFN) model from consideration. ASCO has consistently opposed the ill-advised MFN model, as it would have had a devastating impact on people with cancer. 

August 3, 2021

The Centers for Medicare & Medicaid Services (CMS) released updates to the Inpatient Prospective Payment System (IPPS) for fiscal year (FY) 2022 final rule, including updates to Medicare payment policies and payment rates for most acute care hospitals.

July 29, 2021

The American Society of Clinical Oncology (ASCO) recently published “Telehealth in Oncology: ASCO Standards and Practice Recommendations” in JCO Oncology Practice. The document provides oncology-specific standards for using telehealth to treat individuals with cancer.

July 28, 2021

The Association for Clinical Oncology submitted comments to the CMS regarding provisions in a 2022 Notice of Benefit and Payment Parameters proposed rule on extended and special enrollment provisions for federally-facilitated health insurance exchanges and state-based exchanges on the federal platform.

July 15, 2021

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants.

June 30, 2021

The Association for Clinical Oncology (ASCO) submitted comments to the Centers for Medicare & Medicaid Services in response to two cancer-related provisions in the 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) proposed rule. ASCO’s comments include responses to CMS’ Requests for Information (RFIs) on the transition to digital quality measures and health equity.

June 22, 2021

Delegates from the Association for Clinical Oncology (ASCO) participated in a Special Meeting of the American Medical Association’s (AMA) House of Delegates (HOD), where the HOD voted to approve two ASCO-backed resolutions.

June 22, 2021

In a joint position statement, ASCO and Friends of Cancer Research say individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion.

June 16, 2021

A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation.

June 8, 2021

The COVID-19 pandemic has profoundly interrupted delivery of key preventive services, resulting in many adolescents missing routine human papillomavirus (HPV) vaccine doses. In response, the American Society of Clinical Oncology (ASCO) and nearly 80 National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation’s health care systems, physicians, parents and children, and young adults to get HPV vaccination back on track.

Pages